Scilex Subsidiaries Sell ACEA Pharma to Phoenix Asia in $1B Share Deal

Scilex Holding Company announced that its subsidiaries ACEA Therapeutics, Inc. and ACEA Pharma, Inc. have entered into a definitive agreement to sell 100% of ACEA Pharma's equity to Phoenix Asia Holdings Limited in an all-stock transaction valued at $1 billion. The landmark deal represents a significant capital infusion for the pharmaceutical company while positioning it for a Nasdaq listing in the coming months. The transaction is expected to close by the end of Q2 2026, subject to customary regulatory approvals and stock exchange clearance.

Under the terms of the agreement, Phoenix Asia Holdings Limited will issue newly-issued shares valued at $1 billion to acquire full ownership of ACEA Pharma. Upon closing, Phoenix Asia will be renamed ACEA Pharma and pursue a public listing on Nasdaq, marking a significant milestone for the company's growth trajectory. Notably, ACEA Therapeutics will retain approximately 82% ownership in the combined entity post-closing, maintaining substantial control and alignment of interests with the newly public company.

Strategic Rationale and Deal Structure

This transaction represents a capital-efficient mechanism for ACEA Pharma to secure growth funding while providing Scilex subsidiaries with meaningful ongoing ownership in the business. The $1 billion valuation reflects confidence in ACEA Pharma's portfolio and commercial potential, particularly in specialty pharmaceuticals markets where the company operates.

Key transaction highlights include:

• Transaction value: $1 billion in newly-issued Phoenix Asia shares
• Post-close ownership: ACEA Therapeutics retains ~82% equity stake
• Entity name: Phoenix to be renamed ACEA Pharma upon closing
• Listing venue: Nasdaq public markets
• Expected closing: End of Q2 2026
• Conditions: Subject to regulatory approvals and stock exchange clearance

The all-stock structure suggests both parties value the strategic combination and believe public market access will unlock greater value creation opportunities. By maintaining controlling ownership, ACEA Therapeutics positions itself to benefit from the eventual public market valuation while providing Phoenix Asia shareholders with exposure to ACEA Pharma's pharmaceutical assets and pipeline.

Market Context and Industry Backdrop

The pharmaceutical industry continues to experience robust M&A activity as companies seek growth platforms, pipeline diversification, and access to specialized therapeutic areas. ACEA Pharma's move toward public markets via this transaction reflects broader industry trends favoring specialty pharma companies with focused portfolios and commercial momentum.

The specialty pharmaceutical sector has attracted significant capital as investors recognize opportunities in underserved therapeutic areas and niche patient populations. Public listings in this space have historically commanded premium valuations relative to broader pharma indices, driven by:

• Pipeline depth: Novel therapeutic candidates addressing unmet medical needs
• Market niche expertise: Focused portfolio strategies targeting specific disease states
• Commercial infrastructure: Dedicated sales and marketing capabilities
• Regulatory pathways: Established development programs with known timelines

The Nasdaq listing positions ACEA Pharma to access deeper capital markets, potential M&A currency, and access to institutional investors increasingly focused on specialized pharmaceutical investments. The $1 billion valuation implies market confidence in the company's commercial prospects and pipeline advancement.

Investor Implications and Forward Outlook

For Scilex shareholders, this transaction creates a valuable liquid security in a publicly-traded entity while maintaining significant ongoing exposure through the ~82% stake. The deal structure effectively allows ACEA Therapeutics to realize value without complete divestiture, preserving upside participation in future growth and potential capital appreciation from the Nasdaq listing.

The transaction carries several important implications for the investment community:

• Value realization: $1 billion valuation provides objective market pricing for ACEA Pharma assets
• Liquidity path: Nasdaq listing creates eventual exit opportunities for Scilex shareholders
• Growth positioning: Public company status enables enhanced M&A activity and strategic partnerships
• Capital access: Public markets provide direct funding avenue for clinical development and commercialization
• Investor universe: Nasdaq listing expands potential shareholder base to include institutional investors

The pending Q2 2026 closing timeline provides regulatory authorities adequate review periods while allowing deal parties to address any approval contingencies. Successful completion would represent a significant milestone for Scilex's portfolio company strategy, demonstrating the value creation potential of its subsidiary investments.

As the pharmaceutical industry continues consolidating and specialty pharma segments attract robust investor interest, ACEA Pharma's path to public markets validates the market opportunity in focused therapeutic platforms. The transaction's all-stock structure and Scilex's maintained controlling stake suggest long-term alignment between the parties and confidence in sustainable value creation through the public company phase.